Cancer biomarkers: A systems approach

Nature Biotechnology

Volumn 24, Issue 8, 2006, Pages 905-908

  Hartwell, Lee ^a,c   Mankoff, David ^a   Paulovich, Amanda ^c   Ramsey, Scott ^c,d   Swisher, Elizabeth ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; DNA MARKER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HLA ANTIGEN CLASS 2; IMATINIB; PROSTATE SPECIFIC ANTIGEN;

BRAIN CANCER; BREAST CANCER; CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CEREBROSPINAL FLUID; CHRONIC MYELOID LEUKEMIA; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE METABOLISM; HEALTH CARE COST; HUMAN; LUNG CANCER; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UTERINE CERVIX CANCER;

DIAGNOSIS, COMPUTER-ASSISTED; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 33747065800     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0806-905     Document Type: Note

References (28)

1. Thompson, I.M. et al. J. Am. Med. Assoc. 294, 66-70 (2005).
2. Etzioni, R. et al. Nat. Rev. Cancer 3, 243-252 (2003).
3. Elmore, J.G. et al. N. Engl. J. Med. 338, 1089-1096 (1998).
4. Ford, D. et al. Am. J. Hum. Genet. 62, 676-689 (1998).
5. Madeline, M.M. et al. J. Infect. Dis. 186, 1565-1574 (2002).
6. Hulka, B.S. Cancer screening. Degrees of proof and practical application. Cancer 62 Suppl. 8 1776-1780 (1988).
7. Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: National Cancer Institute, DCCPS. Surveillance Research Program, Cancer Statistics Branch. 〈http://seer.cancer.gov/ faststats/sites.php?site=Ovary%20Cancer&stat=Prevalence〉
8. Kim, J.J., Wright, T.C. & Goldie, S.J. J. Am. Med. Assoc. 287, 2382-2390 (2002).
9. Kelloff, G.J. et al. Clin. Cancer Res. 11, 7967-7985 (2005).
10. Mankoff, D.A. & Krohn, K.A. in Drug Resistance in Cancer. (ed. Teicher, B.) 105-122 (Humana Press, Totowa, NJ, 2006).
11. Linden, H.M. et al. J. Clin. Oncol. 24, 2793-2799 (2006).
12. Mortimer, J.E. et al. J. Clin. Oncol. 19, 2797-2803 (2001).
13. Dehdashti, F. et al. Int. J. Radiat. Oncol. Biol. Phys. 55, 1233-1238 (2003).
14. Rajendran, J.G. & Krohn, K.A. in Positron Emission Tomography: Principles and Practice. (eds. Bailey, D.L., Townsend, D.W., Valk, P.E. & Maisey, M.N.) 689-696 (Springer Verlag, London, 2002).
15. Hendrikse, N.H. et al. Cancer Res. 59, 2411-2416 (1999).
16. Sasongko, L. et al. Clin. Pharmacol. Ther. 77, 503-514 (2005).
17. Belinsky, S.A. et al. Cancer Res. 66, 3338-3344 (2006).
18. Lynch, T.J. et al. N. Engl. J. Med. 350, 2129-2139 (2004).
19. Weber, W.A. J. Nucl. Med. 46, 983-995 (2005).
20. Stroobants, S. et al. Eur. J. Cancer 39, 2012-2020 (2003).
21. Mankoff, D.A., Shields, A.F. & Krohn, K.A. Radiol. Clin. North Am. 43, 153-167 (2005).
22. Theilmann, R.J. et al. Neoplasia 6, 831-837 (2004).
23. Blankenberg, F., Ohtsuki, K. & Strauss, H.W. Q. J. Nucl. Med. 43, 170-176 (1999).
24. Yagle, K.J. et al. J. Nucl. Med. 46, 658-666 (2005).
25. Bonadonna, G. et al. N. Engl. J. Med. 294, 405-410 (1976).
26. Robbins, R.J. et al. J. Clin. Endocrinol. Metab. 91, 498-505 (2006).
27. Quaranta, V., Weaver, A.M., Cummings, P.T. & Anderson, A.R. Clin. Chim. Acta 24, 173-179 (2005).
28. Loeve, F. et al. J. Natl. Cancer Inst. 92, 557-563 (2000).